Navigation Links
Rules-Based Medicine Introduces CardiovascularMAP(TM) Multiplex Biomarker Panel to Aid CVD Drug Development
Date:10/28/2009

AUSTIN, Texas, Oct. 28 /PRNewswire/ -- Rules-Based Medicine (RBM), a leading multiplexed biomarker testing laboratory, today announced the launch of CardiovascularMAP, a research tool designed specifically to advance drug development aimed at the treatment of cardiovascular disease (CVD.) Designed in collaboration with leading pharmaceutical and biotechnology research groups, the 50-biomarker panel combines biomarkers most commonly associated with CVD progression with additional markers to identify new patterns of disease, resulting in a potentially powerful new tool for researchers.

"RBM is providing access to the most comprehensive array of cardiovascular biomarkers ever assembled in one panel," said George P. Rodgers, M.D., F.A.C.C., past chairman of the American College of Cardiology Board of Governors. "Accurate measurement of these biomarkers clearly has the potential to accelerate CVD research programs."

CardiovascularMAP is based on RBM's proprietary Multi-Analyte Profiling (MAP) platform, which quantifies key blood-based biomarkers representing dozens of important biological pathways. The multiplexing process allows for an optimized panel intended to heighten efficiency while providing high levels of accuracy and precision.

"As researchers gain appreciation for the critical role inflammation plays in cardiovascular and other diseases, it is important to combine known CVD biomarkers with those that report on multiple associated pathways," said Craig Benson, RBM president and chief executive officer. "Our multiplexed panel for cardiovascular disease provides researchers with a cost-effective tool to measure established CVD biomarkers while also identifying new biomarker patterns for further exploration."

Cardiovascular disease is the leading cause of morbidity and mortality in the United States. CVD follows a progression that begins with the evolution of risk factors that contribute to the development of subclinical atherosclerosis. Subclinical disease typically goes undetected until the onset of overt CVD marked by symptoms such as chest pain, shortness of breath, dizziness and fainting. Patients with overt CVD have a poor prognosis with increased risk of recurrent events, morbidity, and mortality. Systemic inflammation and abnormal lipoprotein metabolism have been documented as important contributors to the progression of atherosclerotic disease and plaque instability.

Many of the events in the progression of CVD can be monitored using biomarkers found in blood. For a complete list of the CardiovascularMAP analytes and details regarding sample submission, please refer to www.rulesbasedmedicine.com.

About Rules-Based Medicine, Inc.

Rules-Based Medicine (RBM) is a CLIA-certified biomarker testing laboratory that solves complex therapeutic development, diagnostic and treatment challenges with innovative products and services. The Company's proprietary Multi-Analyte Profiling (MAP) platform makes the drug discovery and development process more efficient and effective by providing pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins from small sample volumes. Building on the MAP platform, RBM has developed a host of solutions including: a self-contained whole-blood culture system that brings reproducibility and simplicity to ex vivo immune response measurement; novel and companion diagnostic tests for complex diseases and therapies; therapeutic-specific MAPs custom designed for late-stage clinical development; and new assays for the early detection of renal damage. Additional information on RBM is available via the worldwide web at www.rulesbasedmedicine.com.

CardiovascularMAP(TM) is a trademark of Rules-Based Medicine, Inc.

SOURCE Rules-Based Medicine, Inc.


'/>"/>
SOURCE Rules-Based Medicine, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Mark Popovsky Receives Prominent Award for Leadership in Transfusion Medicine
2. High Blood Pressure Medicines Show Promise For Treating Heart Disease
3. Emergency Medicine Physicians Announces Six New Contracts With North Carolina Hospitals
4. Personalized Medicine Killer Apps Will Transform Care Model
5. Personalized Medicine Expert: Dont Fix It, Predict It
6. Safe Drug Drop Off - Sheriff Baca, LA County Communities, and Narconon Join Together to Get Drugs Out of the Medicine Cabinet
7. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
8. Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine
9. Hard To Treat Diseases (HTDS.PK) Stem Cells and Regenerative Medicine
10. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
11. Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharmaceutical company focused on late-stage drug development, ... Dexcel Pharma of pivotal batches required for ... Drug Administration (FDA). This follows Kitov,s announcement ... III trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... -- A key trend that will boost ... new treatments. Cardax, a development stage life sciences company, ... is expected to fulfil large unmet medical needs in ... to develop new treatments for osteoarthritis. One such study ... osteoarthritis are being investigated, and early trials of stem-cell ...
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... 31, 2016 , ... Splashtop Inc., the worldwide leader in high performance ... the leading provider of secure mobile remote access solution for Japan enterprises. ... remote access solution. Splashtop for CACHATTO will be available as an integrated ...
(Date:5/31/2016)... ... ... Twenty years ago it was revolutionary: enabling the people who hear distressing voices ... But this approach has proven transformative, both for people who hear voices and for ... is used around the world, but it still lags in the United States. , ...
(Date:5/31/2016)... ... May 31, 2016 , ... When ... he knew it was something that contractors should have at their disposal on ... gets,” says Butch, CertainTeed’s Director of Contractor Programs. , As a result, ...
(Date:5/31/2016)... Severna Park, Maryland (PRWEB) , ... May 31, ... ... the ability to attribute calls back to particular advertising campaigns, to monitor the ... teams so that they can maximize conversions and revenue. The software allows customers ...
(Date:5/31/2016)... ... May 31, 2016 , ... Effective leaders not only drive service to ... a whole. On June 2, Northbound CEO Mike Neatherton and COO Paul Alexander will ... the opening plenary on “Leadership: The Journey to Authenticity” with Onsite Workshops CEO Miles ...
Breaking Medicine News(10 mins):